Axovant Sciences to Present at Upcoming Investor Conferences
BASEL, Switzerland, Feb. 27, 2017 /PRNewswire/ -- Axovant Sciences (NYSE: AXON), a leading clinical-stage biopharmaceutical company focused on the treatment of dementia, today announced upcoming presentations at three investor conferences:
- March 6 at 3:20 p.m. ET at the Cowen and Company 37th Annual Healthcare Conference
- March 14 at 10:45 a.m. ET at the Barclays Global Healthcare Conference
- March 22 at 3:55 p.m. ET at the Oppenheimer 27th Annual Healthcare Conference
A simultaneous webcast will be available for each conference in the Investors section of Axovant's website at www.axovant.com. A replay will be available for 30 days following each conference.
About Axovant Sciences Axovant Sciences is a leading clinical-stage biopharmaceutical company focused on acquiring, developing and commercializing novel therapeutics for the treatment of dementia. Axovant intends to develop a pipeline of product candidates to comprehensively address the cognitive, functional and behavioral aspects of dementia and related neurological disorders. Our vision is to become the leading company focused on the treatment of dementia by addressing all forms and aspects of this condition.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/axovant-sciences-to-present-at-upcoming-investor-conferences-300414201.html
SOURCE Axovant Sciences
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- The West Can't Process Enough of This Critical Metal, and the Gap Doesn't Close by 2030
- Small Business, Big Trust: How Local Locksmiths Compete With National Call Centers
- Pump.fun (PUMP) Jumps 17% as Solana Meme Mania Returns, AlphaPepe Still Has Its First Big Pump Ahead
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
Barclays, Cowen & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share